PIRS Pieris Pharmaceuticals Huge Upside Potential

Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS):

AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments
Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments
Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments
SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments
Servier 40Mil upfront payment and 447Mil potential milestone payments
inhaled program PRS-220 for the treatment of IPF. selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis

On 8/16/2021 Morgan Stanley reported 1,675,969 shares of PIRS for $6.42Mil, an increase of +104.6% for an ownership of 2.512% in the company

On 4/26/2021 HC Wainwright brokerage Reiterated Rating to Buy and a price target of $9.00

On 6/30/2021 Jefferies Financial Group brokerage Boosted Price Target to Buy from $6.00 to $8.00

Usually i have price targets lower than most analysts, but on PIRS, my price target is 10usd.

I`m looking forward to read your opinion about it.